PCRX

Pacira BioSciences, Inc. $25.36 1M +7.0% 3M +8.6% YTD +3.7% as of 2026-09-11
Watchlist

next ticker · + or scroll to zoom · pan · 0 reset

▲ buy   ▼ sell  ·  size ≈ trade size  · earnings beat miss  ·  ring before open after close  ·  moving averages · click the buttons above to hide them

Model view — historical tendencies for the days ahead, not a forecast
Next 1 day
-0.1%
Next 1 week
-0.7%
Next 1 month
-0.3%
Seasonality
Weak window historically
Next 30 days (to Oct 14): -2.7% median, 21% of the last 14 years finished up.
20-year seasonality chart →
Mean reversion
Neutral — RSI(2) at 32
RSI(2) under 15 is oversold (this name has historically bounced); over 85 is overbought. Its dip-buy edge in history is -0.21%/day.
Mean-reversion stats →
1-month breakdown — Market · β 0.35 -0.1% · Seasonal tilt -0.2%
$13M/day volume 37% volatility -5% 1-year -79% from ATH
52-week range · 74% of the way up · -8% from the high
$18.80$27.66

Congressional trades in PCRX Full tracker →

1 member · 10 buys / 0 sells · $66K–$290K disclosed · latest filing Aug 26, 2021.

BUY TM Tom Malinowski · traded May 31, 2019 $15K–$50K
BUY TM Tom Malinowski · traded Jan 25, 2021 $1K–$15K
BUY TM Tom Malinowski · traded May 6, 2021 $1K–$15K
BUY TM Tom Malinowski · traded Apr 20, 2021 $1K–$15K
BUY TM Tom Malinowski · traded May 30, 2019 $15K–$50K
BUY TM Tom Malinowski · traded May 31, 2019 $15K–$50K
BUY TM Tom Malinowski · traded Aug 23, 2019 $1K–$15K
BUY TM Tom Malinowski · traded Sep 26, 2019 $15K–$50K

Earnings Full history →

Next report 2026-11-05 (Thursday, after close, in 52 days) · EPS est. 0.72.

1-day std dev
6.7%
Finished up
62%
Biggest pop
+19.4%
Biggest drop
-16.6%

Standard deviation of the close-to-close move over the last 60 reports. History, not a forecast.

Data from the U.S. House Clerk and FINRA, plus end-of-day prices. Not investment advice.